Argent Biopharma Limited (RGT, formerly MGC Pharmaceuticals Ltd), is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. The company's proprietary delivery technologies enhance penetration across the blood-brain and alveolar-capillary barriers, supporting differentiated efficacy and composition-of-matter protection.
Find out what a historical investment in Argent Biopharma would be worth today using our RGT stock calculator.
Buying RGT shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Argent Biopharma in minutes.
Sign up with some I.D. and zero paperwork
Add funds to your account
Make your first investment in RGT
What is the ticker symbol of Argent Biopharma?
The ticker symbol for Argent Biopharma is RGT.
How much is one share of RGT?
One share of RGT is valued at $0.02 as of 20 November 2026.
What is the market capitalisation of Argent Biopharma RGT?
As of 20 November 2026 Argent Biopharma has a market cap of $2.71M.
What is the P/E ratio of RGT?
The Price to Earnings ratio of RGT is -0.26.
What is the Earnings Per Share of RGT?
The Earnings Per Share of RGT is -$0.09.
What is the 52-week high for Argent Biopharma stock?
The Argent Biopharma 52-week high stock price is $0.11.
What is the 52-week low for Argent Biopharma stock?
The Argent Biopharma 52-week low stock price is $0.02.
Can I buy RGT shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?
Yes, the Stake investing platform allows you to buy RGT shares and over 13,000 more stocks and ETFs across the ASX and Wall St.
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.